SLN
Silence Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$12.20
−3.94%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 260.20x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 19.09x
- Price / sales
- 1195.78x
- Price / cash flow
- -17.37x
Enterprise value
- Enterprise value
- $662.6M
- EV / sales
- 1078.67x
- EV / EBITDA
- -10.99x
- EV / EBIT
- -9.91x
- Market cap
- $734.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026